Anticancer drug development in Europe

SENDO is a no-profit academic research organization promoting and coordinating transnational research and early clinical trials in Southern Europe with the aim of boosting research on new anticancer drugs using modern up-to-date methodology.

The search for innovative, more effective and more tolerable anticancer therapy is an unrelenting challenge and an ethical obligation for the scientific community.
Turning a molecule from a promise in the lab into an active drug for patients is a high-priority scientific and social endeavor.

Traditionally the remit of the pharmaceutical industry, the development of new drugs is now rapidly becoming a primary goal also for small biotech companies and academia.

Drug development is also a composite process requiring different skills, from experimental pharmacology to clinical trial methodology. Early clinical research requires a fine balance between the needs of collecting sound experimental evidence and the patients’ medical needs and personal expectations.

SENDO is focused on research and committed to bridging the patients’ and the medical - scientific community’s needs.

SENDO stands for Southern Europe New Drug Organization.